CYP3A4型
药品
药代动力学
药物代谢
药理学
咪唑安定
CYP3A型
体内
生物利用度
异型生物质的
化学
细胞色素P450
药物发现
药效学
新陈代谢
生物
酶
生物化学
生物技术
镇静
作者
Sarvesh Sabarathinam,T. Vijayakumar
出处
期刊:Drug Metabolism Letters
[Bentham Science]
日期:2021-05-05
卷期号:14 (1): 2-4
被引量:6
标识
DOI:10.2174/1872312814666200811110024
摘要
CYP450 enzymes in the liver have a significant role in the metabolism of xenobiotics. Probe drug strategy is broadly used to evaluate the pharmacodynamic and pharmacokinetic drug/ herb-drug interactions/ food-drug interactions. Probe drugs reveal the exact pathway of drug metabolism in the liver by their targeted tractability property. The CYP3A4 isoenzyme metabolizes the majority of the drugs (65%).The characteristics of targeted probe drugs were observed from the admetSAR (version2) online database.Midazolam is widely used as a probe drug because of its peculiar character. Midazolam affirms the accurate and consistent prediction of pharmacokinetic mediated drug interactions even in nanogram concentrations with or without a potent CYP3A inhibitor. Remarkably, midazolam is used as a CYP3A4 substrate in the majority of in vivo studies.It is concluded that midazolam shows a good response in all clinical studies because of its lesser half-life and bioavailability when compared with other probe drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI